ZVSA
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- ZyVersa Therapeutics highlights lipidomic data in Alport Syndrome and diabetic kidney disease reinforcing need for drugs to attenuate damaging renal lipid accumulationSep 3, 2025
- ZyVersa Therapeutics highlights data showing critical need for therapies addressing kidney lipotoxicity to alleviate diabetic kidney disease and its progressionAug 14, 2025
- ZyVersa Therapeutics supports FDA-authorized emergency compassionate use of Cholesterol Efflux Mediator™ VAR 200 in patient with ApoCII amyloidosisJul 10, 2025
- ZyVersa Therapeutics highlights study linking microglia-driven inflammation to Parkinson's and Alzheimer's developmentMay 20, 2025
- ZyVersa unveils the groundbreaking potential of inflammasome inhibitors combined with GLP-1 agonists to address the unmet medical needs of people with obesity.May 7, 2025